Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Protein Degradation Specialist Gets $1bn Up Front

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Stand out from the crowd — Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy

Protein degradation specialist Arvinas, Inc. will receive $1bn up front and accelerate the development of its estrogen receptor protein degrader ARV-471, while Pfizer Inc. gets another opportunity to expand its already significant presence in breast cancer – with the blockbuster CDK4/6 inhibitor Ibrance (palbociclib) – under a deal announced on 22 July for the development and commercialization of Arvinas’ small molecule.

Executives from both companies, during a same-day call with Arvinas investors, acknowledged the competitive environment for the development of oral...